EGRIFTA SV Trademark

Trademark Overview

On Tuesday, November 20, 2018, a trademark application was filed for EGRIFTA SV with the United States Patent and Trademark Office. The USPTO has given the EGRIFTA SV trademark a serial number of 88200431. The federal status of this trademark filing is REGISTERED as of Tuesday, June 16, 2020. This trademark is owned by Theratechnologies Inc.. The EGRIFTA SV trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of lipodystrophy, obesity, wasting, growth hormone deficiency, cognitive impairment and traumatic brain injury
egrifta sv

General Information

Serial Number88200431
Word MarkEGRIFTA SV
Filing DateTuesday, November 20, 2018
Status700 - REGISTERED
Status DateTuesday, June 16, 2020
Registration Number6077575
Registration DateTuesday, June 16, 2020
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 31, 2020

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of lipodystrophy, obesity, wasting, growth hormone deficiency, cognitive impairment and traumatic brain injury

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSaturday, December 8, 2018
Primary Code005
First Use Anywhere DateTuesday, December 3, 2019
First Use In Commerce DateTuesday, December 3, 2019

Trademark Owner History

Party NameTheratechnologies Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressMONTREAL, QUEBEC H2R1X1
CA
Party NameTheratechnologies Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressMontreal. Quebeck H3A1T8
CA
Party NameTheratechnologies Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressMontreal. Quebeck H3A1T8
CA

Trademark Events

Event DateEvent Description
Friday, January 20, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Friday, January 20, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, January 20, 2023TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Friday, January 20, 2023TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Friday, January 20, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, January 20, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, January 20, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, June 16, 2020REGISTERED-PRINCIPAL REGISTER
Tuesday, March 31, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 31, 2020PUBLISHED FOR OPPOSITION
Wednesday, March 11, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, February 26, 2020NOTICE OF ACCEPTANCE OF AMENDMENT TO ALLEGE USE E-MAILED
Tuesday, February 25, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, February 25, 2020USE AMENDMENT ACCEPTED
Monday, February 24, 2020AMENDMENT TO USE PROCESSING COMPLETE
Monday, February 24, 2020USE AMENDMENT FILED
Wednesday, February 12, 2020TEAS AMENDMENT OF USE RECEIVED
Tuesday, October 22, 2019NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Tuesday, October 22, 2019INQUIRY TO SUSPENSION E-MAILED
Tuesday, October 22, 2019SUSPENSION INQUIRY WRITTEN
Tuesday, October 22, 2019ASSIGNED TO EXAMINER
Monday, September 30, 2019SUSPENSION CHECKED ¿ TO ATTORNEY FOR ACTION
Wednesday, September 25, 2019ASSIGNED TO LIE
Sunday, March 3, 2019NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Sunday, March 3, 2019LETTER OF SUSPENSION E-MAILED
Sunday, March 3, 2019SUSPENSION LETTER WRITTEN
Sunday, February 24, 2019ASSIGNED TO EXAMINER
Saturday, December 8, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, November 23, 2018NEW APPLICATION ENTERED

Related Keywords

egrifta cognitive deficiency impairment traumatic injury brain hormone growth treatment preparations